可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Magosaki N, Tsurumi Y, Hosoda S. Current approaches to restenosis after coronary intervation[J].Nippon Rinsho, 1998,56:242.
[2]吕安林,高 歌,贾国良,等.恒磁场对离体兔动脉平滑肌细胞的抑制效应[J].中华理疗杂,2000,23(5):288.
[3] Sprengers ED,Kluft C. Plasminogen activator inhibitors[J] .Blood,1987,69:381.
[4] Malatoni LS, Grassi R, Stancalleni B,et al. Release of immunoreactive endothelin from the heart during percutaneous transluminal coronary angioplasty [J].Am Heart J,1993,126:700.
[5] Walker ID,Davidson JF,Hutton H,et al. Disordered "fibrinolytic potential" in coronary heart disease[J].Thromb Res,1979,10:509.
[6]姚 坤,陈在嘉,陶寿琪.冠心病的纤维蛋白溶解活性[J].中华内科杂志,1987,26:71.
[7] Kanamasa K,Ogawa I,Hayashi T,et al. Prevention of coronary arterial renarrowing by continuous 3-day infusion of tissue plsminogen activator after successful percutaneous transluminal
coronary angioplasty: a randomed, double-blind, placebo-controlled study[J].Angiology, 2000,51(5):367.
[8] Ishiwata S, Tukuda T, Nakanishi T,et al. Postangioplastic restenosis: platelet activation and the coagulationfibrinolysis system as possible factors in the pathogenesis of restenosis[J].Am Heart J,1997,133(4):387.
[9] Roller RE, Janisch S,Carroll V,et al. Changes in the fibrinolytic system in patients with peripheral arterial occlusive disease undergoing percuteneous transluminal angioplasty[J].Thromb Res,1999, 94(4):241.